Cargando…

Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery

FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sari, Cetin, Seip, Richard L., Umashanker, Devika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947603/
https://www.ncbi.nlm.nih.gov/pubmed/33716960
http://dx.doi.org/10.3389/fendo.2021.588016
_version_ 1783663261144580096
author Sari, Cetin
Seip, Richard L.
Umashanker, Devika
author_facet Sari, Cetin
Seip, Richard L.
Umashanker, Devika
author_sort Sari, Cetin
collection PubMed
description FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m(2) prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period.
format Online
Article
Text
id pubmed-7947603
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79476032021-03-12 Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery Sari, Cetin Seip, Richard L. Umashanker, Devika Front Endocrinol (Lausanne) Endocrinology FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m(2) prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7947603/ /pubmed/33716960 http://dx.doi.org/10.3389/fendo.2021.588016 Text en Copyright © 2021 Sari, Seip and Umashanker https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Sari, Cetin
Seip, Richard L.
Umashanker, Devika
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
title Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
title_full Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
title_fullStr Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
title_full_unstemmed Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
title_short Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m(2) Prior to Bariatric Surgery
title_sort case report: off label utilization of topiramate and metformin in patients with bmi ≥50 kg/m(2) prior to bariatric surgery
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947603/
https://www.ncbi.nlm.nih.gov/pubmed/33716960
http://dx.doi.org/10.3389/fendo.2021.588016
work_keys_str_mv AT saricetin casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery
AT seiprichardl casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery
AT umashankerdevika casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery